Real-time Container Closure Integrity Testing on the Production Line
Prevent defects and costly product loss with non-destructive CCIT
Destructive testing is often accepted as a necessary component of quality control, but its implications extend well beyond the loss of individual samples. Each destroyed unit represents lost product, time, and data, and at scale this practice steadily undermines efficiency, confidence, and margins. In pharmaceutical, food, and beverage manufacturing, destructive testing disrupts operational continuity by removing products from saleable inventory, wasting product and packaging, delaying batches while results are generated, and forcing quality decisions to rely on limited snapshots rather than comprehensive insight.
The financial and regulatory consequences compound over time. Costs are not confined to the test itself, but include repeated sampling, rework, investigations, and the need for conservative safety buffers, all of which accumulate across shifts, production lines, and sites. From a regulatory standpoint, decision makers remain accountable for ensuring product integrity through appropriate and justified controls. Heavy reliance on destructive testing increases the burden of defending assumptions, sampling strategies, and release decisions during audits and inspections, placing additional pressure on organisations to justify both their processes and outcomes.
Who this is for:
- Pharmaceutical manufacturers operating high-speed vial or bottle filling lines
- QA and production teams responsible for GMP compliance
- OEMs and system integrators building inspection or packaging equipment
Limitations of Manual Deterministic Sampling
Traditional container closure integrity testing is typically performed off-line using destructive deterministic methods. While these methods can be compliant with regulatory expectations, they inherently examine only a small fraction of the total batch. The majority of containers remain untested, and results are only available after production has finished.
Because testing is destructive and time-consuming, it cannot be applied continuously or at scale. If a process deviation occurs early in the batch, it may remain undetected until hundreds of thousands of containers have already been produced. This creates blind spots in quality assurance and turns integrity testing into a reactive rather than preventive activity.
In-line CCIT as a Preventive Quality Approach
Inline container closure integrity testing changes the role of quality control within pharmaceutical manufacturing. Instead of verifying quality after the fact, inline CCIT enables continuous monitoring of container integrity directly on the production line.
By testing every container in real time and without destruction, deviations can be detected at the moment they occur. This allows operators to intervene immediately, correct process issues, and prevent defects from propagating through the rest of the batch. Inline CCIT therefore functions not only as a quality assurance tool but also as an active process control mechanism.
Gasporox In-line CCIT Solutions for Pharma Manufacturing
Gasporox offers inline CCIT solutions that support different integration strategies, depending on the level of automation and system responsibility required by the manufacturer or line builder.
VialArch™ and BottleArch™ are sensor-based solutions designed for independent integration into pharmaceutical production lines. These sensors are embedded by OEMs, system integrators, or end users into existing inspection or packaging equipment, allowing flexible adaptation to specific line architectures and container formats. This approach is well suited for manufacturers seeking tight integration into proprietary systems or customized inspection solutions.
For manufacturers looking for a complete, ready-to-use solution, Gasporox also offers LineArch™, a fully integrated inline CCIT machine. LineArch™ is delivered as a standalone system designed for straightforward installation on the production line, minimizing integration effort and implementation time. It provides the same real-time, non-destructive testing principles while offering a standardized, turnkey approach.
Together, these options allow pharmaceutical manufacturers to choose between sensor-level integration and a complete in-line CCIT machine, depending on technical requirements, internal resources, and line ownership models.
VialArch™
BottleArch™
LineArch
Technical Capabilities and Compliance Alignment
Gasporox in-line CCIT systems perform real-time analysis of every container passing through the line. As the testing is non-destructive, containers do not need to be removed from production, and no consumables are required. Automated detection and traceability ensure that deviations are clearly identified and documented, supporting both operational decision-making and regulatory expectations.
This approach aligns with the intent of Annex 1 and USP <1207>, supporting the adoption of non-destructive, deterministic testing methods and reinforcing a science-based quality strategy. In-line CCIT enables manufacturers to demonstrate control, consistency, and risk mitigation across the entire batch.
Operational and Regulatory Impact
Manufacturers that implement in-line CCIT benefit from earlier detection of container closure defects, significantly reducing the risk of large-scale product loss. By identifying deviations in real time, waste is minimized, batch release can be accelerated, and investigations become more focused and data-driven.
At the same time, in-line CCIT strengthens compliance by providing continuous evidence of process control. This improves audit readiness and supports a proactive quality culture, while also protecting patient safety and brand reputation.
Scalable Quality Control Across Lines and Sites
In-line CCIT solutions from Gasporox are designed to scale across different container formats, production lines, and manufacturing sites. This enables pharmaceutical companies to standardize their integrity testing strategy globally, reducing dependence on manual sampling and ensuring consistent quality performance across facilities.
Such scalability is particularly valuable for manufacturers operating multiple sites or planning future capacity expansions.
Key Takeaways
Late detection of container closure defects is not an isolated issue but a structural weakness in traditional quality control strategies. Manual deterministic sampling leaves significant blind spots and limits the ability to act before losses occur. Inline, 100% real-time CCIT addresses this gap by enabling immediate detection and corrective action while supporting compliance with Annex 1 and USP <1207>. Gasporox solutions provide a scalable path toward preventive, data-driven container integrity testing for both vials and infusion bottles.
Strengthen Your CCIT Strategy
Outdated quality control methods continue to expose pharmaceutical manufacturers to unnecessary financial and regulatory risk. Inline CCIT provides a practical way to detect issues earlier, reduce waste, and strengthen compliance.
Contact Gasporox to discuss how inline container closure integrity testing can improve control and resilience in your production strategy.
